ITC-6146RO

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameITC-6146RO
Drug Alias NameITC6146ROITC-6146-RO
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > OHPAS linker
Mechanisms of ActionImmunomodulatorsAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAb Studio IncIntoCell
China Registration ClassN/A

Develop Information

Active CompaniesIntoCell IncIntoCellAb Studio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A